Creative medical technology holdings announces evolutionary development of its ipscelz® program with the successful generation of ipsc derived islet cells that produce human insulin

Phoenix, june 24, 2024 (globe newswire) -- creative medical technology holdings, inc. (“creative medical technology” or the “company”) (nasdaq: celz), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced that it has successfully generated human induced pluripotent stem cells (ipsc)-derived islet cells that produce human insulin.
CELZ Ratings Summary
CELZ Quant Ranking